# A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

> **NCT06937749** · PHASE2 · RECRUITING · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 165 (estimated)

## Conditions studied

- Metabolic Dysfunction-associated Steatohepatitis (MASH)

## Interventions

- **DRUG:** Placebo
- **DRUG:** IBI362

## Key facts

- **NCT ID:** NCT06937749
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-07-22
- **Target enrollment:** 165 (ESTIMATED)
- **Last updated:** 2025-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06937749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06937749, "A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06937749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*